(2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
. pharmacoepidemiology
(2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
. (2023). Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. The Lancet Regional Health - Europe, 27, 100579. http://doi.org/https://doi.org/10.1016/j.lanepe.2022.100579
. (2023). "Take up to eight tablets per day": Incorporating free-text medication instructions into a transparent and reproducible process for preparing drug exposure data for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5595
. (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874
. (2022). Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvac043
. (2022). Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments. Clin Epidemiol, 14, 641-652. http://doi.org/10.2147/clep.s360843
. (2022). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension. J Psychopharmacol, 2698811221082470. http://doi.org/10.1177/02698811221082470
. (2022). Does co-prescribing non-steroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15371
. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021
.